サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1504940

がん悪液質市場、シェア、規模、動向、産業分析レポート：療法別、作用機序別、流通チャネル別、地域別、セグメント別予測、2024年～2032年

Cancer Cachexia Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Progestogens, Corticosteroids, Combination Therapy, and Others); By Mechanism of Action; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

出版日
ページ情報
英文 118 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
がん悪液質市場、シェア、規模、動向、産業分析レポート：療法別、作用機序別、流通チャネル別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年05月01日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のがん悪液質市場規模は2032年までに34億3,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

特に老年人口におけるがんの有病率の激増と、悪液質の重要性に関するヘルスケア専門家の意識の高まりが、世界市場の成長に寄与しています。がん患者の増加に伴い、個人におけるがん悪液質の発症リスクも上昇しています。

例えば、GLOBOCAN 2022のデータによると、2022年にがんに罹患した人の53％以上が65歳以上です。世界の高齢化人口が急速に増加しており、2022年には7億6,000万人、2050年には16億人に増加すると予想されているため、がんの有病率も増加する可能性が高いです。

がん研究を支援し、先進的な治療法や薬剤の市場開拓を促進する政府の取り組みも増えており、市場の成長を後押ししています。がん悪液質に対処するために特別に開発された新しい新規治療法の開発に携わっている主な製薬企業があります。

例えば、2023年8月、Actimed Therapeutics社は、がん悪液質およびその他多くの筋消耗性疾患の治療のために475万ポンドを調達したと発表しました。この資金は、同社の開発を継続し、IMPACT臨床開発プログラムの準備を確実にするために活用されます。

がんは40～79歳の死因の第1位であり、がん患者の80％が悪液質と関連し、約20％の患者ががん悪液質により死亡しています。この複雑な病態に関するさらなる研究と、悪液質と関連する特定の分子経路に狙いを定めた標的治療の開発が強く求められています。

例えば、2023年9月、Actimed Therapeutics社は、非小細胞肺がん患者に伴う悪液質治療薬S-pindolol benzoateの第2b/3相臨床試験のIND申請が米国FDAから承認されたと発表しました。

がん悪液質市場レポートハイライト

2023年には、治療効率の高さと抗炎症作用の存在から、黄体ホルモン薬セグメントが注目すべきシェアを占めました。

食欲刺激剤セグメントは2023年に大半のシェアを占めたが、これは体型と体格を維持するためにがん患者に広く採用されていることに起因しています。

流通チャネルに分類されるオンライン薬局セグメントは、処方箋管理や時間節約などの機能によりオンライン薬局の人気が高まっているため、予測期間中に最も高いCAGRで成長すると予測されます。

北米は、確立されたヘルスケアのインフラが存在し、がんの有病率が高いことから、世界市場を独占しています。

主な市場プレイヤーは、Aeterna Zentaris、ANI Pharmaceuticals、Merck &Co.Inc.、TCI Peptide Therapeutics、Teva Pharmaceutical Industriesなどです。

目次

第1章 イントロダクション

  • レポート概要
    • 調査目的
    • 市場範囲
    • 前提条件
  • 利害関係者

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のがん悪液質市場の洞察

  • 流通チャネルスナップショット
  • がん悪液質市場力学
    • 促進要因と機会
      • がん悪液質の罹患率増加が世界市場の成長を牽引
      • 研究開発活動への投資増加が市場の成長を促進
    • 抑制要因と課題
      • 高額な治療費と厳しい規制
  • PESTEL分析
  • がん悪液質市場の流通チャネルの動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界のがん悪液質市場：療法別

  • 主な調査結果
  • イントロダクション
  • プロゲストーゲン
  • コルチコステロイド
  • 併用療法
  • その他

第6章 世界のがん悪液質市場：作用機序別

  • 主な調査結果
  • イントロダクション
  • 食欲増進剤
  • 減量安定剤

第7章 世界のがん悪液質市場：流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 世界のがん悪液質市場：地域別

  • 主な調査結果
  • イントロダクション
    • がん悪液質市場評価：地域別、2019-2032年
  • 北米
    • 北米：療法別、2019年～2032年
    • 北米：流通チャネル別、2019年～2032年
    • 北米：作用機序別、2019年～2032年
    • 米国
    • カナダ
  • 欧州
    • 欧州：療法別、2019年～2032年
    • 欧州：流通チャネル別、2019-2032年
    • 欧州：作用機序別、2019-2032年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
  • アジア太平洋地域
    • アジア太平洋地域：療法別、2019年～2032年
    • アジア太平洋地域：流通チャネル別、2019年～2032年
    • アジア太平洋地域：作用機序別、2019年～2032年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
  • 中東・アフリカ
    • 中東・アフリカ：療法別、2019年～2032年
    • 中東・アフリカ：流通チャネル別、2019-2032年
    • 中東・アフリカ：作用機序別、2019年～2032年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：療法別、2019年～2032年
    • ラテンアメリカ：流通チャネル別、2019-2032年
    • ラテンアメリカ：作用機序別、2019-2032年
    • メキシコ
    • ブラジル
    • アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • AbbVie Inc.（US）
  • Actimed Therapeutics（UK）
  • Aeterna Zentaris Inc.（Canada）
  • ANI Pharmaceuticals Inc.（US）
  • Aphios Corporation（US）
  • Aveo Pharmaceuticals Inc.（US）
  • Bristol-Myers Squibb Company（US）
  • Helsinn Group（Switzerland）
  • Hikma Pharmaceuticals PLC（UK）
  • Merck & Co. Inc.（US）
  • Mylan N.V.（US）
  • Pfizer Inc.（US）
  • TCI Peptide Therapeutics（US）
  • Teva Pharmaceutical Industries Ltd.（Israel）
図表

List of Tables

  • Table 1 Global Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 2 Global Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 3 Global Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 4 Cancer Cachexia Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 6 North America: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 7 North America: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 8 U.S.: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 9 U.S.: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 10 U.S.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Canada: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 12 Canada: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 13 Canada: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Europe: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 15 Europe: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 16 Europe: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 UK: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 18 UK: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 19 UK: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 20 France: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 21 France: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 22 France: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Germany: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 24 Germany: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 25 Germany: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 Italy: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 27 Italy: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 28 Italy: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 Spain: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 30 Spain: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 31 Spain: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Russia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 36 Russia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 37 Russia: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 China: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 42 China: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 43 China: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 44 India: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 45 India: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 46 India: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Japan: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 51 Japan: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 52 Japan: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 56 South Korea: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 57 South Korea: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 58 South Korea: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 65 UAE: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 66 UAE: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 67 UAE: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 68 Israel: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 69 Israel: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 70 Israel: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 71 South Africa: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 72 South Africa: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 73 South Africa: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 Latin America: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 75 Latin America: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 76 Latin America: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 77 Mexico: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 78 Mexico: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 79 Mexico: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 80 Brazil: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 81 Brazil: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 82 Brazil: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 83 Argentina: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • Table 84 Argentina: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • Table 85 Argentina: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Cancer Cachexia Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Mechanism of Action
  • Figure 7. Global Cancer Cachexia Market, by Mechanism of Action, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Therapeutics
  • Figure 9. Global Cancer Cachexia Market, by Therapeutics, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Cancer Cachexia Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 12. Cancer Cachexia Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Cancer Cachexia Market
目次
Product Code: PM4913

The global cancer cachexia market size is expected to reach USD 3.43 billion by 2032, according to a new study by Polaris Market Research. The report "Cancer Cachexia Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Progestogens, Corticosteroids, Combination Therapy, and Others); By Mechanism of Action; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The drastic increase in the prevalence of cancer, especially among the geriatric population, and growing awareness among healthcare professionals about the significance of cachexia contribute to the global market growth. With the increase in cancer patients, the risk of developing cancer cachexia among individuals also rises.

For instance, according to the GLOBOCAN 2022 data, more than 53% of people who had cancer in 2022 were aged 65 years or above. As the world's ageing population is growing rapidly, with 760 million people in 2022, and is expected to rise to 1.6 billion people by 2050, the prevalence of cancer is also likely to increase.

A growing number of government initiatives supporting cancer research and promoting the development of advanced therapies and drugs also propelled the market's growth. There are key pharmaceutical companies involved in the development of new novel therapies that are specifically developed for addressing cancer cachexia.

For instance, in August 2023, Actimed Therapeutics, announced that they have raised £4.75 million for the treatment of cancer cachexia and many other muscle wasting disorders. The fund will be utilized to continue the development of the company and ensure the preparation of the IMPACT clinical development program.

Cancer remains the leading cause of death for people between the ages of 40-79 years old, and 80% of cancer cases are associated with cachexia, and approx. 20% of patients die due to cancer cachexia; there is a significant need for further studies regarding its complex condition and the development of targeted therapies that are aimed at the specific molecular pathways associated with cachexia.

For instance, in September 2023, Actimed Therapeutics, announced that they have received approval from US FDA for their IND application for Phase 2b/3 clinical study of the S-pindolol benzoate for the treatment of cachexia that are associated with patients with non-small cell lung cancer.

Cancer Cachexia Market Report Highlights

The Progestogens segment accounted for a notable share in 2023, on account of its greater efficiency in treatment and the presence of anti-inflammatory properties.

Appetite stimulators segment held the majority share in 2023, which is attributed to its widespread adoption by cancer patients for maintaining body shape and mass.

The online pharmacy segment categorized under the distribution channel is predicted to grow at the highest CAGR during the forecast period due to the growing popularity of online pharmacies due to its features like prescription management and time-saving.

North America dominated the global market, owing to the presence of well-established healthcare infrastructure and the significant prevalence of cancer.

The key market players include Aeterna Zentaris, ANI Pharmaceuticals, Merck & Co. Inc., TCI Peptide Therapeutics, and Teva Pharmaceutical Industries.

Polaris Market Research has segmented the cancer cachexia market report based on therapeutics, mechanism of action, distribution channel, and region:

Cancer Cachexia, Therapeutics Outlook (Revenue - USD Billion, 2024 - 2032)

  • Progestogens
  • Corticosteroids
  • Combination Therapy
  • Others

Cancer Cachexia, Mechanism of Action Outlook (Revenue - USD Billion, 2024 - 2032)

  • Appetite Stimulators
  • Weight Loss Stabilizers

Cancer Cachexia, Distribution Channel Outlook (Revenue - USD Billion, 2024 - 2032)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Cancer Cachexia, Regional Outlook (Revenue - USD Billion, 2024 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East and Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Cancer Cachexia Market Insights

  • 4.1. Cancer Cachexia Market - Distribution Channel Snapshot
  • 4.2. Cancer Cachexia Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of cancer cachexia cases to drive global market growth
      • 4.2.1.2. Rising investments in R&D activities spurring market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High treatment costs and stringent regulations
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Cancer Cachexia Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Cancer Cachexia Market, by Therapeutics

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
  • 5.3. Progestogens
    • 5.3.1. Global Cancer Cachexia Market, by Progestogens, by Region, 2019-2032 (USD Billion)
  • 5.4. Corticosteroids
    • 5.4.1. Global Cancer Cachexia Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
  • 5.5. Combination Therapy
    • 5.5.1. Global Cancer Cachexia Market, by Combination Therapy, by Region, 2019-2032 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global Cancer Cachexia Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Cancer Cachexia Market, by Mechanism of Action

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • 6.3. Appetite Stimulators
    • 6.3.1. Global Cancer Cachexia Market, by Appetite Stimulators, by Region, 2019-2032 (USD Billion)
  • 6.4. Weight Loss Stabilizers
    • 6.4.1. Global Cancer Cachexia Market, by Weight Loss Stabilizers, by Region, 2019-2032 (USD Billion)

7. Global Cancer Cachexia Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Hospital Pharmacy
    • 7.3.1. Global Cancer Cachexia Market, by Hospital Pharmacy, By Region, 2019-2032 (USD Billion)
  • 7.4. Retail Pharmacy
    • 7.4.1. Global Cancer Cachexia Market, by Retail Pharmacy, By Region, 2019-2032 (USD Billion)
  • 7.5. Online Pharmacy
    • 7.5.1. Global Cancer Cachexia Market, by Online Pharmacy, By Region, 2019-2032 (USD Billion)

8. Global Cancer Cachexia Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Cancer Cachexia Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Cancer Cachexia Market - North America
    • 8.3.1. North America: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
    • 8.3.2. North America: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.3.4. Cancer Cachexia Market - U.S.
      • 8.3.4.1. U.S.: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.3.5. Cancer Cachexia Market - Canada
      • 8.3.5.1. Canada: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • 8.4. Cancer Cachexia Market - Europe
    • 8.4.1. Europe: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.4.4. Cancer Cachexia Market - UK
      • 8.4.4.1. UK: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.4.5. Cancer Cachexia Market - France
      • 8.4.5.1. France: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.4.6. Cancer Cachexia Market - Germany
      • 8.4.6.1. Germany: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.4.7. Cancer Cachexia Market - Italy
      • 8.4.7.1. Italy: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.4.8. Cancer Cachexia Market - Spain
      • 8.4.8.1. Spain: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.4.9. Cancer Cachexia Market - Netherlands
      • 8.4.9.1. Netherlands: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.4.10. Cancer Cachexia Market - Russia
      • 8.4.10.1. Russia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • 8.5. Cancer Cachexia Market - Asia Pacific
    • 8.5.1. Asia Pacific: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.5.4. Cancer Cachexia Market - China
      • 8.5.4.1. China: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.5.5. Cancer Cachexia Market - India
      • 8.5.5.1. India: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.5.6. Cancer Cachexia Market - Malaysia
      • 8.5.6.1. Malaysia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.5.7. Cancer Cachexia Market - Japan
      • 8.5.7.1. Japan: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.5.8. Cancer Cachexia Market - Indonesia
      • 8.5.8.1. Indonesia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.5.9. Cancer Cachexia Market - South Korea
      • 8.5.9.1. South Korea: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • 8.6. Cancer Cachexia Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.6.4. Cancer Cachexia Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.6.5. Cancer Cachexia Market - UAE
      • 8.6.5.1. UAE: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.6.6. Cancer Cachexia Market - Israel
      • 8.6.6.1. Israel: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.6.7. Cancer Cachexia Market - South Africa
      • 8.6.7.1. South Africa: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
  • 8.7. Cancer Cachexia Market - Latin America
    • 8.7.1. Latin America: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.7.4. Cancer Cachexia Market - Mexico
      • 8.7.4.1. Mexico: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.7.5. Cancer Cachexia Market - Brazil
      • 8.7.5.1. Brazil: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
    • 8.7.6. Cancer Cachexia Market - Argentina
      • 8.7.6.1. Argentina: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie Inc. (US)
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Actimed Therapeutics (UK)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3.Aeterna Zentaris Inc. (Canada)
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. ANI Pharmaceuticals Inc. (US)
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Aphios Corporation (US)
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Aveo Pharmaceuticals Inc. (US)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Bristol-Myers Squibb Company (US)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Helsinn Group (Switzerland)
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Hikma Pharmaceuticals PLC (UK)
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Merck & Co. Inc. (US)
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Mylan N.V. (US)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Pfizer Inc. (US)
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. TCI Peptide Therapeutics (US)
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Teva Pharmaceutical Industries Ltd. (Israel)
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development